Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment

Chen‐Hua Liu(National Taiwan University Hospital), Jia‐Horng Kao(National Taiwan University Hospital), Tsai‐Yuan Hsieh(Tri-Service General Hospital), Wei‐Yu Kao(Taipei Medical University Hospital), Chung‐Hsin Chang(Fu Jen Catholic University), Jow-Jyh Huang(St. Martin de Porres Hospital), Pei‐Lun Lee(Jacobi Medical Center), Po‐Yueh Chen(Chia-Yi Christian Hospital), Yo-Jen Fang(National Taiwan University Hospital), Kuo‐Chih Tseng(Buddhist Tzu Chi General Hospital), Chi‐Yang Chang(E-Da Hospital), Chi-Yi Chen(Chia-Yi Christian Hospital), Sheng‐Shun Yang(Taichung Veterans General Hospital), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Taichung Veterans General Hospital), Chih‐Wei Tseng(Tzu Chi University), Chun‐Jen Liu(National Taiwan University), Jyh-Jou Chen(Chi Mei Medical Center), Pei–Yuan Su(Changhua Christian Hospital), Ke-Jhang Huang(China Medical University), Ming‐Chang Tsai(Chung Shan Medical University Hospital), Gin‐Ho Lo(E-Da Hospital), Yi‐Jie Huang(Taichung Veterans General Hospital), Hsueh‐Chou Lai(China Medical University), Chia‐Sheng Huang(Kaohsiung Medical University), Fu‐Jen Lee(Fu Jen Catholic University), Yu‐Lueng Shih(Tri-Service General Hospital), Chun‐Chao Chang(Taipei Medical University Hospital)
Gut
January 6, 2021
Cited by 39


Related Papers